Compass Therapeutics (NASDAQ:CMPX) Price Target Raised to $6.00 at Piper Sandler

Compass Therapeutics (NASDAQ:CMPX) had its price objective increased by Piper Sandler from $4.00 to $6.00 in a report released on Friday morning,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

A number of other equities analysts have also recently commented on CMPX. Wall Street Zen cut Compass Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Stifel Nicolaus set a $6.00 price target on Compass Therapeutics in a report on Monday, June 1st. Canaccord Genuity Group lowered their price target on Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, April 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $24.00 target price on shares of Compass Therapeutics in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Compass Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $11.77.

Compass Therapeutics Trading Up 8.0%

Shares of NASDAQ CMPX opened at $2.15 on Friday. Compass Therapeutics has a 12-month low of $1.61 and a 12-month high of $6.88. The firm’s 50-day moving average price is $2.09 and its 200-day moving average price is $3.86. The stock has a market capitalization of $387.19 million, a price-to-earnings ratio of -5.37 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities analysts predict that Compass Therapeutics will post -0.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Compass Therapeutics in the second quarter worth $24,707,000. Deutsche Bank AG purchased a new stake in shares of Compass Therapeutics during the second quarter valued at $294,000. Simplicity Wealth LLC purchased a new stake in shares of Compass Therapeutics during the second quarter valued at $80,000. Bank of New York Mellon Corp bought a new position in shares of Compass Therapeutics in the second quarter worth about $769,000. Finally, State of Wyoming bought a new position in shares of Compass Therapeutics in the second quarter worth about $31,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.